A Phase II, Open-label Study of INNO-206 in Patients With Recurrent Extensive Small Cell Lung Cancer After First-line Platinum-based Therapy.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2012
At a glance
- Drugs Aldoxorubicin (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 17 Nov 2008 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 22 May 2007 New trial record.